Analyst Research Report Snapshot

Title:

BTG - EU NOD FOR LEMTRADA

Price:

$10.00

Provider:

Edison Investment Research

Date:

01 Jul 2013

Pages:

4

Type:

AcrobatPDF

Companies referenced:

BTG.L

Available for Immediate Download
Summary:

The positive European regulatory opinion on Lemtrada (multiple sclerosis therapy) points to EU approval in Q313 and potential launch shortly thereafter. The recommended indication represents, in our view, a best case scenario for BTG and partner Sanofi. Separately, an FDA decision on Lemtrada is expected late-2013. With the positive EU opinion adding 10p to our risk-adjusted DCF, our new fair value for BTG is 510p.

Why buy analyst research?

  • Institutional quality research
  • Available for Immediate Download
  • Detailed company or industry insight
  • Print or save
  • 24 hour customer support
Return to previous page without adding this item to your cart.
Email Customer Support.

About Analyst Research

Analyst research reports are available for immediate download after purchase. You will have unlimited access to the report for 24 hours after purchase, to download, print or save it as many times as you wish. Analyst Research provided by Reuters does not constitute investment advice, and is not endorsed by Reuters Research. This information is protected by copyright and intellectual property laws. More information on Analyst Research.